Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine , vol
Vomiting is likely and the chance of asphyxiation on your own vomit is greatly increased
45 A barrier to DPP-4 inhibitor use has been the lack of evidence of CV risk reduction in patients with clinical ASCVD
European journal of haematology , 110 (2), 123-130.
Per il trattamento dellobesit o del sovrappeso legato a patologie , luso di questi farmaci , invece, relativamente pi recente e non tutti sono stati autorizzati in Italia
But all of this is still very new in terms of how to manage patients effectively.For the study, researchers looked at the use of semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro) among patients undergoing weight-loss surgery, analyzing nearly 365,000 patients between 2018 and 2024.The proportion of patients who received at least one GLP-1 prescription in the year leading up to their surgery exploded to more than 29% in the fourth quarter of 2024 from just under 2% in the first quarter of 2020, results show.Among patients without type 2 diabetes, GLP-1 drug use before weight-loss surgery increased to 23% in the fourth quarter of 2024 from 2% in the first quarter of 2020, researchers found.GLP-1 use among patients with type 2 diabetes was even higher, rising to 45% from 11% during the same period.The median age of the patients was 43, and they had a median preoperative body mass index (BMI) of 46
